Chugai Pharmaceutical Co Ltd - Company Profile
Powered by
All the data and insights you need on Chugai Pharmaceutical Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Chugai Pharmaceutical Co Ltd Strategy Report
- Understand Chugai Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd., that develops biopharmaceuticals and therapeutic antibodies for the treatment of cancer, bone and joint diseases, renal diseases, autoimmune diseases, neurological and other diseases. The company’s focused R&D activities, improved financial performance, technology platforms and strategic alliance with Roche are its major strengths, even as increase in debt could be a cause for concern to the company. Chugai could benefit from strategic agreements, regulatory approval and strategic initiatives. However, failure to comply with government regulations, influx of generics and increasing competition could affect the company’s performance.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer